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Abstract
Aspergillus fumigatus is commonly found in the respiratory secretions of patients with cystic ﬁbrosis (CF). Although allergic bronchopul-
monary aspergillosis (ABPA) is associated with deterioration of lung function, the effects of A. fumigatus colonization on lung function in
the absence of ABPA are not clear. This study was performed in 259 adults and children with CF, without ABPA. A. fumigatus coloniza-
tion was deﬁned as positivity of >50% of respiratory cultures in a given year. A cross-sectional analysis was performed to study clinical
characteristics associated with A. fumigatus colonization. A retrospective cohort analysis was performed to study the effect of A. fumiga-
tus colonization on lung function observed between 2002 and 2007. Longitudinal data were analysed with a linear mixed model. Sixty-
one of 259 patients were at least intermittently colonized with A. fumigatus. An association was found between A. fumigatus colonization
and increased age and use of inhaled antibiotics. In the longitudinal analysis, 163 patients were grouped according to duration of coloni-
zation. After adjustment for confounders, there was no signiﬁcant difference in lung function between patients colonized for 0 or 1 year
and patients with 2–3 or more than 3 years of colonization (p 0.40 and p 0.64) throughout the study. There was no signiﬁcant differ-
ence in lung function decline between groups. Although colonization with A. fumigatus is more commonly found in patients with more
severe lung disease and increased treatment burden, it is not independently associated with lower lung function or more severe lung
function decline over a 5-year period.
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Introduction
Cystic ﬁbrosis (CF) is characterized by chronic infection of
the airways, in which Pseudomonas aeruginosa is the most
important pathogen. Chronic infection with P. aeruginosa is
associated with increased morbidity and mortality [1]. Fila-
mentous fungi such as Aspergillus fumigatus are also com-
monly found in respiratory secretions of patients.
Reported prevalence rates of colonization in patients with
CF vary, ranging from 6% to 58% [2–11]. The variation in
the reported prevalence has been hypothesized to be
attributable to the age of patients and climatic conditions
[8]. Colonization with A. fumigatus is deﬁned as the pres-
ence of A. fumigatus in respiratory secretions, and is differ-
ent from the main clinical manifestation of A. fumigatus in
CF, allergic bronchopulmonary aspergillosis (ABPA). This
condition is characterized by pulmonary inﬁltrates and the
production of IgG and IgE antibodies speciﬁc for A. fumiga-
tus, as well as a rise in total IgE [2]. The prevalence
of ABPA varies between 2% and 8%, and lung function
has been shown to deteriorate over time in relation to
A. fumigatus sensitization and ABPA [12].
The effect of colonization with A. fumigatus on lung func-
tion in the absence of ABPA is not clear. Case reports of
patients colonized with A. fumigatus whose respiratory dete-
rioration did not respond to antibiotics, but was brought to
a halt by antifungal therapy, suggest a direct negative effect
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of A. fumigatus on pulmonary condition [13]. Recently, a
longitudinal study has shown that chronic infection with
A. fumigatus is associated with increased hospitalization [14].
However, in several cross-sectional studies, there was no
independent relationship between colonization and lung dis-
ease [6,11].
We aimed to study whether colonization with A. fumigatus
was associated with unfavourable clinical outcome, by evaluat-
ing factors independently associated with A. fumigatus coloniza-
tion and by longitudinally studying the effect of the duration of
A. fumigatus colonization on the course of lung function.
Methods
Patient selection
The CF centre in Utrecht currently provides care for approxi-
mately 350 patients. Patients undergo a routine yearly multi-
disciplinary examination, the results of which are prospectively
recorded in a database. Demographics, CF genotype, body
mass index (BMI) values and pulmonary function data were
collected from the database, and were recorded during the
yearly routine examination, which is considered to be a
moment of stability in patients’ clinical condition. BMI Z-scores
were calculated on the basis of growth curves [15].
Patients were selected for two separate analyses. The
ﬁrst was a cross-sectional analysis of data from 2007, to
study which factors were associated with A. fumigatus colo-
nization, in order to generate a hypothesis on the effect of
A. fumigatus colonization in our patient population. In this
analysis, all patients who were under treatment at the cen-
tre and who had been seen for routine care in 2007 were
included. Patients were excluded if they were chronically
infected with Burkholderia cepacia complex, if they had a his-
tory of lung transplantation or ABPA (deﬁned according to
diagnostic criteria [16]) and if they did not have pulmonary
function or microbiology data available for 2007. The sec-
ond analysis aimed to investigate the longitudinal effect of
A. fumigatus colonization on lung function, to further study
the hypothesis generated by the cross-sectional analysis; a
retrospective cohort analysis was performed, in which all
patients who were regularly followed at the CF centre
from 2002 to 2007 (a minimum of 4 years of lung function
measurements and microbiology data) and who had a lung
function measurement performed in 2002 (to ensure a
baseline lung function value) were included. All patients
gave written informed consent for storage and evaluation
of their clinical data in the CF database for scientiﬁc
purposes, and the use of this database is permitted by the
ethical board.
Microbiology
Sputum or throat swab samples were taken at each visit at
the CF centre from all patients. A. fumigatus and P. aeruginosa
colonization status were investigated by evaluating cultures
performed between 2002 and 2007. All samples were cul-
tured according to the standard diagnostic laboratory proto-
col, which included testing for fungi. Colonization with
A. fumigatus in a given calendar year was deﬁned as the pres-
ence of A. fumigatus in >50% of respiratory cultures per-
formed in that year. Patients were categorized according to
the number of years during the observation period in which
they met the criteria for A. fumigatus colonization.
Statistical analysis
For the cross-sectional data, simple logistic regression was
performed to evaluate the association between the study
variables and the dependent variable (A. fumigatus coloniza-
tion). In order to study which variables were independently
associated with the outcome variable, variables showing an
association (p <0.10) were entered into a multiple logistic
regression model, using the ‘enter’ method. The number of
variables in the model was limited to ensure at least ten out-
come events per independent variable [17].
Patients were divided into categories according to the
number of years during the observation period in which they
met the criteria for A. fumigatus colonization (group 1, no
colonization or 1 year, group 2, 2–3 years; and group 4,
4 years or more).
Differences among the three groups during the ﬁrst year
of observation were evaluated by the Kruskal–Wallis test
(for non-normally distributed continuous variables),
ANOVA (for normally distributed continuous variables) or
the chi-square test (for dichotomous variables). A linear
mixed model was used to evaluate the effect of A. fumigatus
colonization on lung function during the 5-year study per-
iod. The model assumed a linear trend in forced expiratory
volume in 1 s (FEV1) as a percentage of predicted over
time for each patient, and allowed for random patient-spe-
ciﬁc slope and intercept. First, a basic model was created,
with A. fumigatus colonization group, and random slope for
time. To this model, several possible confounders (variables
associated with colonization in the cross-sectional analysis
or those different for the three groups at baseline) were
added, to check whether this signiﬁcantly improved the
model ﬁt.
A difference in decline of FEV1 among the three groups
was tested by examining the improvement in model ﬁt after
addition of an interaction term to the model (time · group).
This interaction term would allow for different slopes over
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time for the three groups. SPSS version 15.0 for Windows
was used for all statistical analyses.
Results
Cross-sectional analysis
In 2007, 335 patients visited the CF centre for an annual
check-up. Of these patients, seven were excluded because
they had a history of lung transplantation, and ﬁve were
excluded because they were chronically infected with
B. cepacia complex. Nine patients did not have samples for
respiratory culture taken at the CF centre, 24 did not have
lung function data available for 2007 (20 were too young
for pulmonary function testing, and four did not have pul-
monary function test data available), and 31 were excluded
because of a history of ABPA. In total, 259 were available
for analysis.
Simple logistic regression indicated a signiﬁcant association
between the presence of A. fumigatus colonization in 2007
and increased age, decreased FEV1, chronic P. aeruginosa
infection, increased number of hospitalizations, and increased
use of inhaled antibiotics and recombinant human DNase
(Table 1). In total, six variables with a p-value of <0.10 in the
simple logistic regression were entered into the multiple
logistic regression model: age, FEV1, number of hospitaliza-
tions, inhaled antibiotic use, recombinant human DNase use
and chronic P. aeruginosa infection. In the ﬁnal model,
A. fumigatus colonization was independently associated with
increased age (p 0.02 and p 0.09 for age categories 13–24
and ‡25 years, respectively, vs. reference category
0–12 years) and the use of inhaled antibiotics (p 0.001).
Longitudinal analysis
Between 2002 and 2007, there were 225 patients who regu-
larly visited the CF centre (at least 4 years of lung function
and microbiology data available). Six patients were excluded
because of a history of lung transplantation, and 30 patients
were excluded because they had (developed) ABPA. Four
patients were excluded because of chronic B. cepacia com-
plex infection. Twenty-two patients did not have lung func-
tion data for 2002 available (20 because they were too
young for spirometry, and two because they did not have
their lung function measured at this CF centre). In total, 163
patients were included in the longitudinal analysis.
There were differences in possible confounding clinical
and demographic characteristics between the three groups:
patients with longer duration of colonization were older
(p <0.001), were more likely to use inhaled antibiotics
(p <0.001), had more hospitalizations (p 0.02), had lower
FEV1 values (p <0.001) and had lower BMI Z-scores (p 0.04)
(Table 2).
With regard to the decline in FEV1 in time, patterns were
rather similar for the three groups (Fig. 1). The differences
in FEV1 between the groups were explained by the investi-
gated possible confounders (the use of inhaled antibiotics,
BMI Z-score, age at baseline and number of hospitalizations)
rather than by the presence of A. fumigatus colonization. As
shown in Table 3, the three groups had a signiﬁcantly differ-
ent estimate for FEV1 in the unadjusted model, and this dif-
ference disappeared after adjustment for confounders.
Adjustment for the number of cultures performed per year
did not change the difference in estimates between the three
groups, and this variable was therefore not included in the
model. Including an interaction term between FEV1 patterns
TABLE 1. Simple and multiple logistic regression analysis showing an independent association between Aspergillus fumigatus
colonization and age and inhaled antibiotic use (n = 259 patients), with A. fumigatus colonization (deﬁned as >50% of cultures
positive in 2007) as dependent variable
Colonized
(n = 61)
Not colonized
(n = 198)
Simple logistic regression Multiple logistic regression
p OR (95% CI) p OR (95% CI)
Age category, n (%)
0–12 years (reference category) (n = 106) 10 (16.4) 96 (48.5) <0.001 0.06
13–24 years (n = 99) 33 (54.1) 66 (33.3) <0.001 4.80 (2.2–10.4) 0.02 2.90 (1.2–7.0)
‡25 years (n = 54) 18 (29.5) 36 (18.2) <0.001 4.80 (2.0–11.4) 0.09 2.39 (0.9–6.5)
Male, n (%) 27 (44.3) 112 (56.6) 0.09 0.61 (0.3–1.1)
dF508 homozygosity, n (%) 38 (63.3) 116 (61.7) 0.82 1.07 (0.6–2.0)
Pancreatic insufﬁciency, n (%) 52 (85.2) 170 (85.9) 0.91 0.95 (0.4–2.2)
CF-related diabetes, n (%) 8 (13.1) 20 (10.1) 0.51 1.34 (0.6–3.2)
FEV1% predicted mean (SD) 63.6 (25.0) 81.5 (25.5) <0.001 0.97
a (0.96–0.99) 0.31 0.99a (0.98–1.01)
BMI Z-score, mean (SD) )0.62 (1.00) )0.38 (1.02) 0.11 0.80a (0.6–1.1)
Inhaled antibiotics, n (%) 40 (65.6) 49 (24.7) <0.001 5.79 (3.1–10.8) 0.001 3.72 (1.7–8.2)
rhDNase, n (%) 34 (55.7) 66 (33.3) 0.002 2.52 (1.4–4.5) 0.58 1.21 (0.6–2.4)
Chronic Pseudomonas aeruginosa infection, n (%) 43 (70.5) 80 (40.4) <0.001 3.52 (1.9–6.5) 0.99 0.99 (0.4–2.3)
Number of hospitalizations, mean (SD) 0.67 (SD 1.3) 0.29 (SD 0.7) 0.01 1.47a (1.1–2.0) 0.27 1.20a (0.9–1.7)
BMI, body mass index; CF, cystic ﬁbrosis; FEV1, forced expiratory volume in 1 s; rhDNase, recombinant human DNase; SD, standard deviation.
aChange per unit of variable.
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and time, in both the unadjusted and adjusted model, failed
to improve model ﬁt signiﬁcantly. This further conﬁrms that
there was no signiﬁcant difference in the slope of lung func-
tion between the three groups. The overall decline in FEV1
was 1.30% points per year (Table 3).
Discussion
The results presented here suggest that colonization with
A. fumigatus, in the absence of ABPA, does not have a nega-
tive effect on the course of lung function on a population
level over a 5-year period.
Several other studies have investigated the association
between A. fumigatus colonization and lung function cross-
sectionally. The results from the cross-sectional analysis
performed in the present study are similar to those reported
by Milla et al. An unadjusted association between lung func-
tion and A. fumigatus colonization was found that was no
longer signiﬁcant after adjustment for covariates and
appeared to be explained by age and gender [6], indicating
that the increased risk of advanced pulmonary disease was
associated with demographic factors that have been reported
to be associated with severity of lung disease [18]. Another
cross-sectional study by Bargon et al. also found no signiﬁ-
cant association between A. fumigatus colonization (deﬁned
as at least two cultures positive out of a minimum of four)
and lung function, in a population of adult CF patients. Simi-
lar to our ﬁndings, a signiﬁcant association with inhaled anti-
biotics was found [11]. The authors suggest that the use of
prophylactic antibiotics may have predisposed the patients to
A. fumigatus colonization. This has also been suggested from
a study on the use of inhaled tobramycin, in which the isola-
tion of A. fumigatus was increased in the treatment group, at
the end of the study period [19]. On the basis of our ﬁnd-
ings, it is difﬁcult to say whether there is a causal relation-
ship between the use of inhaled antibiotics and A. fumigatus
colonization, as the association was already present at the
start of the observation period. However, as logistic regres-
sion analysis of the cross-sectional results showed an inde-
pendent association between the presence of A. fumigatus
(even after correction for severity of lung disease by cor-
recting for FEV1) and the use of inhaled antibiotics, a causal
relationship seems possible.
As a causal relationship between colonization and deterio-
ration of lung function cannot be inferred from a cross-
sectional analysis, we also performed a longitudinal study.
Patients who were chronically colonized throughout the
study period had lower lung function than patients who were
colonized for <4 years during the study period. However,
TABLE 2. Group differences in possible confounding factors
during ﬁrst year of the observation period
Group 1
(n = 115)
Group 2
(n = 29)
Group 3
(n = 19) p
Age (years), median (IQR) 11 (7–18) 14 (10–19) 21 (13–29) <0.001
Male, n (%) 63 (54.8) 15 (51.7) 9 (47.4) 0.82
dF508 homozygosity, n (%) 77 (68.8) 16 (57.1) 14 (73.7) 0.41
Pancreatic insufﬁciency, n (%) 98 (85.2) 21 (75.0) 17 (89.5) 0.33
CF-related diabetes, n (%) 15 (13.0) 3 (10.3) 5 (26.3) 0.25
Inhaled antibiotics, n (%) 10 (8.7) 7 (24.1) 11 (57.9) <0.001
rhDNase, n (%) 21 (18.3) 5 (17.2) 5 (26.3) 0.68
>50% cultures positive for
Pseudomonas aeruginosa, n (%)
37 (39.4) 13 (56.5) 11 (61.1) 0.12
FEV1% predicted mean (SD) 83.9 (22.8) 73.3 (20.4) 61.3 (22.7) <0.001
Number of hospitalizations,
median (IQR)
0 (0–0) 0 (0–1) 0 (0–0) 0.02
BMI Z-score, mean (SD) )0.46 (1.01) )0.57 (1.08) )1.10 (1.07) 0.04
BMI, body mass index; CF, cystic ﬁbrosis; FEV1, forced expiratory volume in 1 s;
IQR, interquartile range; rhDNase, recombinant human DNase; SD, standard
deviation.
Patients were grouped according to duration of Aspergillus fumigatus colonization
(>50% of cultures positive for A. fumigatus in a given year) during the observa-
tion period (from 2002 to 2007): group 1, 0–1 years of A. fumigatus coloniza-
tion; group 2, 2–3 years; and group 4, ‡4 years. Signiﬁcant differences between
three groups were tested with the chi-square test for dichotomous variables,
with the Kruskal–Wallis test for non-normally distributed continuous variables,
or with ANOVA for normally distributed continuous variables.
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FIG. 1. Mean forced expiratory volume in 1 s (FEV1) per group over
the study period: group 1 (n = 115), 0–1 years of Aspergillus fumiga-
tus colonization; group 2, (n = 29), 2–3 years; and group 4 (n = 19),
‡4 years.
TABLE 3. Lung function estimates for the three groups
based on the mixed model analysis, showing no statistically
signiﬁcant difference in lung function between the three
groups after adjustment for covariates
Variable
Unadjusted Adjusteda
Estimate95% CI Estimate95% CI
Intercept 84.73 80.73 to )88.73104.85 99.55 to )110.15
Time )1.30 )1.75 to )0.86 )1.32 )1.75 to )0.88
Aspergillus fumigatus colonization
Group 1 (0–1 year) 0 0
Group 2 (2–3 years) )9.93 )18.70 to )1.16 )3.08 )10.20 to 4.04
Group 3 (‡4 years) )23.41 )33.85 to )12.96 )2.25 )11.64 to )7.13
aAdjusted for baseline body mass index Z-score, age at baseline, number of hos-
pitalizations, and years of inhaled antibiotic use.
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this difference was no longer statistically signiﬁcant after
adjustment for confounders. Most importantly, there was no
statistically signiﬁcant difference in decline in lung function
between the three groups of patients, suggesting that, within
a time frame of 5 years, A. fumigatus colonization does not
determine the decline in lung function. These ﬁndings differ
from a recent longitudinal analysis in children with CF. Amin
et al. [14] also found that patients with persistent A. fumiga-
tus infection had lower lung function than patients who were
not persistently infected (deﬁned as two or more positive
cultures per year). However, it was not reported whether
there was a difference in decline between these patients.
The possibility of detection bias is a limitation of our
study. More severely affected patients are more likely to visit
the CF centre, more likely to produce sputum and, there-
fore, more likely to be sampled. This was partly accounted
for by deﬁning A. fumigatus colonization as a proportion of all
cultures performed in a year (>50% positive). Furthermore,
the mean number of cultures performed per year was cor-
rected for in the model, but because this did not change the
difference in lung function estimate between the three colo-
nization groups, this factor was removed. Another limitation
is the possibility of incomplete collection of respiratory cul-
ture data, as some patients are not exclusively under treat-
ment at the CF centre and are sometimes seen in the
outpatient departments of non-CF centre hospitals. Further-
more, in the present study we excluded patients with ABPA,
because the aim of the study was to look at the effect of
A. fumigatus colonization in the absence of ABPA. However,
we did not include measurements of speciﬁc antibodies to
A. fumigatus in our analysis, which means that there could
have been patients who did not fulﬁl the criteria of ABPA,
but who were sensitized to A. fumigatus. As sensitization to
A. fumigatus has been shown to be associated with deteriora-
tion in lung function [12], this could have inﬂuenced the data.
The difﬁculty in studying the effect of A. fumigatus coloni-
zation in the present study lies in the fact that, from the
start of the observation period, the three groups differed in
many respects: patients had worse lung function, higher age
and decreased nutritional status with increased duration of
colonization, similar to what was found in the cross-sectional
analysis. It is not clear whether these patients had decreased
lung function because they had been colonized before the
start of the observation period, or whether they were colo-
nized because of more severely damaged lungs. The latter
explanation would be in accordance with the ﬁnding that col-
onization with A. fumigatus is uncommon in young children,
and initial colonization occurs at a later age than colonization
with bacterial pathogens such as Staphylococcus aureus and
P. aeruginosa [20]. In the present study, more insights into
the causality of A. fumigatus colonization have been obtained
by analysing longitudinal follow-up data and evaluating poten-
tial confounders. The results suggest that, as there is no
effect of prolonged colonization on the course of lung func-
tion during the observation period, the decreased pulmonary
function at baseline is not likely to have been caused by A. fu-
migatus colonization. However, as in some other studies,
A. fumigatus was more frequently found in patients with
more severe lung disease and with increased treatment bur-
den. Therefore, although an effect on decline in lung function
in this study could not be found, further prospective studies
are needed to deﬁnitively study causal relationships between
A. fumigatus colonization and treatment burden and pulmo-
nary exacerbations, and the effect of antifungal treatment on
clinical outcome in colonized patients.
Conclusion
This study shows that patients with A. fumigatus colonization
have less favourable clinical status and have a greater burden
of treatment. However, over a 5-year period, colonization
with A. fumigatus in the absence of ABPA is not indepen-
dently associated with a more severe decline in lung function.
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